{"meta":{"document_type":"Research Topic Analysis — Final Peer-Reviewed","topic_id":"3.5","title":"Fecal Secretory IgA and Mucosal Immune Function in Celiac Disease","version":"2.0","status":"FINAL — post peer review","created":"2026-02-10","last_updated":"2026-02-10T22:00:00Z","authoring_model":"Claude Opus 4.6","peer_review":{"reviewer":"Claude Opus 4.6 (twin instance)","verdict":"Accept with major revisions","scientific_quality_score":"8.5/10","clinical_utility_score":"8/10","corrections_applied":["Shiner & Ballard date corrected: 1975 → 1973 (PMID 4586081)","SNCD prevalence corrected: '5-15%' → '1.7-2.7% under strict criteria'","Kappler 2006 journal corrected: attributed to J Pediatr Gastroenterol Nutr","'100% sensitivity' for TG2-IgA deposits qualified with caveat re impaired mucosal IgA","Siniscalco extrapolation hedging strengthened throughout","TACI/TNFRSF13B discussion added as highest-priority workup","Salivary IgA added as critical discriminating test","IgG temporal trend (decline during strict GFD 2013-2019) integrated","Vaccine response testing added to recommendations","Internal contradiction resolved (impaired production vs assumed 100% deposit positivity)","Explicit evidence tiering added (Established / Emerging / Novel hypothesis)"]},"patient_context":{"age":55,"sex":"male","key_diagnoses":["HLA-DQ8+ celiac disease (Marsh 3a, 2013)","Low IgG with selective IgG1 subclass deficiency","Low fecal secretory IgA with normal serum IgA","Ochratoxin A exposure (15× reference)","Mycophenolic acid exposure (2.3× reference)","Type 2 diabetes (diet-controlled)"]},"parent_document":"RCA v4 (14_rca_findings_immune_CD_2026-02-02_v4)"},"core_immunological_data":{"immunoglobulins":{"IgG_total":{"current":{"value":5.2,"unit":"g/L","date":"2025-09-10"},"reference_range":"6.1-14.9","status":"LOW","trend":{"2012":6.3,"2019":5.6,"2022":5.7,"2025_sept":5.2,"2025_dec":5.5,"2026_jan":5.3,"critical_observation":"IgG declined from 6.3 to 5.6 g/L during STRICT GFD (2013-2019)","interpretation":"Decline during optimal dietary compliance strengthens case for PRIMARY immunodeficiency"}},"IgG1":{"value":2.6,"unit":"g/L","reference_range":"4.1-10.1","status":"LOW","percent_of_lower_limit":63,"latest_value":{"value":2.8,"date":"2026-01-30"}},"IgG2":{"value":2.47,"unit":"g/L","reference_range":"1.69-7.86","status":"NORMAL"},"IgG3":{"value":0.17,"unit":"g/L","reference_range":"0.11-0.85","status":"NORMAL"},"IgG4":{"value":0.093,"unit":"g/L","reference_range":"0.030-2.010","status":"NORMAL"},"IgA_serum":{"value":1.6,"unit":"g/L","reference_range":"0.70-4.3","status":"NORMAL","trend":{"2009":1.8,"2012":1.8,"2013":2.1,"2019":2.5,"2022":1.7,"2025_sept":1.5,"2025_dec":1.6}},"IgA_secretory_fecal":{"value":"<280","unit":"µg/mL","reference_range":"510-2040","status":"SEVERELY LOW","percent_of_lower_limit":"<55%","measurement_date":"2025"},"IgA_dissociation_pattern":{"present":true,"interpretation":"Normal serum IgA + severely low fecal sIgA = transport/secretion defect, not production defect"},"IgM":{"value":0.88,"unit":"g/L","reference_range":"0.40-2.1","status":"NORMAL"},"IgE":{"value":"<2","unit":"kU/L","reference_range":"<120","status":"NORMAL"}},"celiac_disease":{"diagnosis_date":"2013","biopsy_grade":"Marsh 3a","HLA_type":"DQ8 positive, DQ2 negative","diet_timeline":{"2013_to_2019":"STRICT gluten-free diet (6 years)","2019_to_2025":"INTERMITTENT gluten exposure (Christmas, events, lapses)","2022_onwards":"Grain-free (stricter than GFD alone, but still intermittent gluten lapses)"},"current_activity_markers":{"steatorrhea":{"present":true,"stool_fat":"4.2 g/100g (ref <3.5)"},"protein_malabsorption":{"present":true,"stool_protein":"1.5 g/100g (ref 0-1.0)"}}},"mycotoxins":{"ochratoxin_A":{"value":"15× reference","mechanism":"B-cell apoptosis, impaired CSR, MALT damage, phenylalanyl-tRNA synthetase inhibition","half_life":"~35 days in humans","chelation":"Cholestyramine binds with 96% efficiency"},"mycophenolic_acid":{"value":"2.3× reference","mechanism":"IMPDH inhibition → blocks de novo purine synthesis → inhibits B and T cell proliferation","clinical_equivalent":"Active metabolite of mycophenolate mofetil (CellCept)","relevance":"Pharmacologically active immunosuppressant at environmental exposure levels"}}},"pathophysiology_model":{"summary":"Compartmentalized mucosal autoimmunity with convergent triple-hit immunodeficiency","core_concept":"Active celiac autoimmunity persists below serological detection threshold due to converging defects in mucosal IgA production, IgA epithelial transport, and B-cell function","components":{"component_1_primary":{"name":"Probable TACI or CSR genetic defect","evidence_tier":"ESTABLISHED biology; CLINICAL PRIORITY for testing","mechanism":"Class switch recombination defect → selective IgG1 deficiency → impaired downstream IgA via sequential switching","evidence_for":["Selective IgG1 deficiency pattern (IgG2/3/4 all normal)","IgG DECLINED from 6.3→5.6 during 6 years of STRICT GFD (2013-2019)","OTA alone would not explain selective IgG1 pattern","TACI prevalence in similar presentations: 8-17%"],"evidence_against":["OTA exposure throughout period is confounder","Cannot confirm until genetic testing completed"],"reversibility":"NOT reversible if present","testing":"TACI/TNFRSF13B genetic testing — HIGHEST PRIORITY"},"component_2_secondary":{"name":"Celiac epithelial damage causing pIgR dysfunction","evidence_tier":"EMERGING — logical but pIgR in celiac unmeasured","mechanism":"Villous atrophy → loss of differentiated epithelium → reduced pIgR-expressing surface area → impaired IgA transcytosis","key_evidence":{"normal_serum_IgA":"Production intact (1.6 g/L)","low_secretory_IgA":"Transport/secretion impaired (<280 µg/mL)","shiner_1973_backflow":"Shiner & Ballard (Gut, 1973; PMID 4586081) showed sIgA 'backflow' into basement membrane in untreated celiac, reversible on GFD","literature_gap":"No study has directly quantified pIgR expression in celiac Marsh 3 biopsies"},"important_caveat":"Pro-inflammatory cytokines (TNF-α, IFN-γ) in celiac should UPREGULATE pIgR transcription via NF-κB — so dysfunction may reflect impaired function despite normal/elevated expression, not reduced expression. This is INFERRED from phenotype, not directly measured.","timeline_implication":"Current sIgA measured during intermittent gluten period (2019-2025) — may reflect RECENT reversible damage","reversibility":"LIKELY REVERSIBLE with complete mucosal healing (6-12 months strict GFD)"},"component_3_secondary":{"name":"Dual mycotoxin immunotoxicity (OTA + MPA)","evidence_tier":"ESTABLISHED for individual toxins; NOVEL for synergistic combination","mechanism":{"OTA":"Direct B-cell toxicity, impaired CSR, MALT structural damage","MPA":"IMPDH inhibition → purine synthesis block → B/T cell proliferation inhibited","combined":"Additive/synergistic immunosuppression disproportionately targeting sequential CSR (requires two rounds of proliferation-dependent switching)"},"reversibility":"REVERSIBLE with toxin clearance (5-6 months after exposure cessation)"}},"double_hit_hypothesis":{"evidence_tier":"NOVEL HYPOTHESIS — mechanistically coherent, untested","description":"IgG1 deficiency reduces mucosal IgA production (Hit 1) while celiac epithelial damage reduces IgA transport (Hit 2), producing multiplicative reduction in fecal sIgA","hit_1_production":"IgG1 deficiency → fewer IgG1+ intermediates in Peyer's patches → impaired sequential CSR to IgA → fewer high-affinity IgA plasma cells","hit_2_transport":"Celiac villous atrophy (Marsh 3a) → reduced pIgR-expressing surface area → impaired transcytosis of whatever dimeric IgA is produced","consequence":"Even modestly reduced production × modestly reduced transport = severely depleted fecal sIgA"},"triple_hit_addition":{"evidence_tier":"NOVEL HYPOTHESIS","description":"Dual mycotoxins (OTA + MPA) add a third layer of B-cell suppression, compounding both production and function defects","pharmacological_logic":"MPA inhibits de novo purine synthesis required for B-cell proliferation during CSR; sequential switching (IgM→IgG1→IgA) requires two rounds of CSR and is disproportionately vulnerable"}},"key_scientific_findings":{"anti_TG2_gut_origin":{"evidence_tier":"ESTABLISHED","summary":"Anti-TG2 antibodies originate in intestinal lamina propria, not systemic circulation","key_data":{"di_niro_2012":"TG2-specific plasma cells = ~10% (range 4-24%) of all duodenal IgA-secreting cells in active CD","marzari_2001":"Anti-tTG isolated from ALL intestinal phage display libraries, NOT from peripheral blood (n=3; small sample limits generalizability)","iversen_2017":"Clonal relatedness between gut and serum anti-TG2 IgA supports gut origin with bone marrow seeding (spillover model)","lindeman_2024":"Chronic naive B cell recruitment drives extrafollicular anti-TG2 response using restricted IGHV5-51 germline"}},"TG2_IgA_tissue_deposits":{"evidence_tier":"ESTABLISHED","summary":"TG2-targeted IgA deposits present in seronegative celiac disease at near-universal sensitivity","key_data":{"salmi_2006":"22/22 (100%) EMA-negative celiac patients had TG2-IgA mucosal deposits (PMID 16571636)","koskinen_2010":"261 untreated patients — 100% positive (PMID 19779364)","korponay_szabo_2004":"Deposits precede villous atrophy — earliest detectable celiac marker (PMID 15082580)"},"sensitivity_caveat":"100% sensitivity demonstrated in patients with normal IgA production capacity. In this patient with potentially impaired mucosal anti-TG2 IgA production (IgG1 deficiency affecting sequential CSR), deposits could theoretically be diminished or absent. Sensitivity in combined SNCD + IgG subclass deficiency is UNKNOWN.","recommendation":"Frozen biopsy TG2-IgA immunofluorescence remains highest-yield diagnostic test despite this caveat"},"sequential_class_switching":{"evidence_tier":"EMERGING","summary":"Gut mucosal IgA can be generated through sequential IgM→IgG1→IgA class switch recombination","citation":{"authors":"Siniscalco ER et al.","title":"Sequential class switching generates antigen-specific gut IgA from IgG1 B cells","journal":"Immunity","year":2025,"volume":"58(12)","pages":"3075-3093.e6","doi":"10.1016/j.immuni.2025.10.022","pmid":"41253159"},"key_findings":{"mouse":"Sγ1 switch region remnants in IgA plasma cells prove prior IgG1 expression; IgG1+ B cells in Peyer's patch subepithelial dome undergo TGF-β-driven switching to IgA","human":"Bone marrow and adenoid tissue show IgA1-IgG1 as most frequent clonal pair among preferentially expanded clones","limitation_1":"Human data from bone marrow and adenoid tissue, NOT directly from human GALT/Peyer's patches","limitation_2":"Proportion of mucosal IgA from sequential vs direct switching unquantified in humans","limitation_3":"No published study has measured fecal sIgA in isolated IgG1 deficiency patients"},"patient_application":{"hypothesis":"IgG1 deficiency (2.6 g/L, ref 4.1-10.1) → reduced IgG1+ intermediates available for sequential CSR in Peyer's patches → impaired high-affinity mucosal IgA generation","confidence":"NOVEL HYPOTHESIS — mechanistically sound but entirely untested","testable_predictions":["IgG1-deficient patients should have lower fecal sIgA than controls (population study needed)","IgG1 restoration (if possible) should improve fecal sIgA","Peyer's patch biopsies in this patient should show reduced IgG1+ GC B cells"]}},"seronegative_celiac_prevalence":{"evidence_tier":"ESTABLISHED","modern_estimate":"1.7-2.7% under strict Paris Consensus criteria","historical_estimates":"12.7-37.9% under loose criteria (1998-2006)","key_references":{"volta_2016":"1.7% (PMID 27352981)","schiepatti_2022":"Strict criteria validation"},"correction_note":"Earlier draft stated '5-15%' which conflated old and new data inappropriately"},"pIgR_transport_in_celiac":{"evidence_tier":"EMERGING — logical but directly unmeasured","established_biology":"pIgR is sole mechanism for epithelial IgA transcytosis; expression regulated by TNF-α, IFN-γ via NF-κB","celiac_evidence":{"shiner_1973":"sIgA 'backflow' into basement membrane in untreated celiac, reversible on GFD (Gut 1973; PMID 4586081)","pIgR_knockout_mice":"Dramatically increased serum IgA + markedly decreased fecal IgA (Shimada 1999; PMID 10553061)"},"critical_gap":"No study has directly quantified pIgR expression in celiac Marsh 3 biopsies","paradox":"Pro-inflammatory cytokines in celiac should upregulate pIgR transcription — dysfunction may be functional (damaged epithelium) rather than transcriptional"},"fecal_antibody_testing_failure":{"evidence_tier":"ESTABLISHED","summary":"Fecal anti-tTG sIgA has only 10% sensitivity (Kappler et al., J Pediatr Gastroenterol Nutr, 2006; PMID 16377644)","reasons":"Proteolytic degradation during colonic transit; tissue-binding sequesters antibodies","alternative":"GIP testing detects antigen (resistant gliadin peptides) rather than antibody response"}},"discriminating_tests":{"salivary_IgA":{"priority":"CRITICAL — highest discriminating value","rationale":"Distinguishes systemic vs gut-specific secretory defect","interpretation":{"if_LOW":{"meaning":"Systemic B-cell homing/differentiation defect across all mucosal sites","supports":"TACI/genetic hypothesis","action":"Prioritize genetic testing — confirms primary defect"},"if_NORMAL":{"meaning":"Gut-specific transport defect","supports":"Celiac-mediated pIgR dysfunction hypothesis","action":"Focus on mucosal healing — better prognosis"}}},"TACI_genetic_testing":{"priority":"HIGHEST for workup","gene":"TNFRSF13B","prevalence_in_similar_cases":"8-17%","rationale":"IgG decline during strict GFD supports genetic etiology; selective IgG1 pattern consistent with pathway-specific CSR defect","if_positive":"Confirms primary immunodeficiency (non-reversible); family screening implications"},"vaccine_responses":{"priority":"HIGH","tests":["Pneumococcal polysaccharide (Pneumovax-23) — T-independent","Tetanus/diphtheria — T-dependent"],"interpretation":{"if_impaired":"Functional immunodeficiency — may warrant IVIG evaluation","if_normal":"Reassuring for infection risk"}},"TG2_IgA_immunofluorescence":{"priority":"HIGH — most informative for celiac confirmation","method":"Frozen duodenal biopsy, double-color immunofluorescence","expected_sensitivity":"96-100% in adult seronegative CD (Salmi 2006, Koskinen 2010)","caveat_for_this_patient":"Sensitivity may be reduced given potentially impaired mucosal anti-TG2 IgA production"},"stool_GIP":{"priority":"MODERATE — compliance verification","sensitivity":"100% for ≥250 mg gluten; 71% for 50 mg","window":"Peak detection 12-36 hours post-exposure"},"B_cell_phenotyping":{"priority":"MODERATE","markers":"CD27+IgD−IgM− switched memory B cells","rationale":"Assess B-cell maturation and class switching capacity"},"serial_fecal_sIgA":{"priority":"MODERATE — treatment monitoring","rationale":"Biomarker for mucosal immune reconstitution after strict GFD + mycotoxin clearance","expected_improvement":"If celiac-mediated component dominant, should improve over 6-12 months"},"IL2_release_assay":{"priority":"EMERGING — when available","caveat":"Sensitivity only 56% for HLA-DQ8+ (this patient); 90% for DQ2.5+","implication":"Negative result uninformative for this HLA-DQ8+ patient"}},"clinical_action_plan":{"immediate":{"timeframe":"Within 1-2 weeks","actions":[{"intervention":"Return to STRICT GFD","rationale":"Patient intermittent 2019-2025; essential for mucosal healing","urgency":"HIGH"},{"intervention":"Salivary IgA measurement","rationale":"Critical discriminating test for systemic vs gut-specific defect","urgency":"HIGH"},{"intervention":"Cholestyramine 4g BID","rationale":"Binds OTA with 96% efficiency; accelerates clearance","duration":"6 months minimum","monitoring":"Repeat OTA at 3 and 6 months"},{"intervention":"Professional mold inspection and remediation","rationale":"Eliminate ongoing OTA/MPA source","urgency":"HIGH"}]},"short_term":{"timeframe":"Within 3 months","tests":[{"test":"TACI/TNFRSF13B genetic testing","priority":"HIGHEST","rationale":"8-17% prevalence; IgG decline during strict GFD supports genetic etiology"},{"test":"Vaccine responses (Pneumovax-23 + tetanus/diphtheria)","priority":"HIGH","interpretation":"Functional humoral immunity assessment"},{"test":"B-cell phenotyping by flow cytometry","priority":"MODERATE","markers":"CD27+IgD−IgM− switched memory B cells"},{"test":"Repeat OTA and MPA levels","timing":"3 months after cholestyramine start","expected":">50% reduction"},{"test":"Stool GIP testing","rationale":"Objectively verify GFD compliance"},{"test":"Family screening","who":"All household members","what":"Immunoglobulins + OTA/MPA levels"}]},"medium_term":{"timeframe":"6-12 months","milestone":"After OTA clearance confirmed AND 6+ months strict GFD","tests":["Repeat immunoglobulin panel with subclasses","Repeat fecal secretory IgA","Consider repeat duodenal biopsy with TG2-IgA immunofluorescence on frozen tissue"],"decision_points":{"if_IgG_improving":{"interpretation":"OTA component was significant; genetic component mild or absent","action":"Continue conservative management with monitoring"},"if_IgG_stable_or_declining":{"interpretation":"Primary immunodeficiency confirmed","action":"Pursue extended genetic panel; consider IVIG if recurrent infections"},"if_sIgA_improving":{"interpretation":"Mucosal component was celiac-mediated and reversible","action":"Continue strict GFD; good prognosis for mucosal immunity"}}},"what_to_avoid":[{"test":"Fecal antibody testing","reason":"6-10% sensitivity; worse with impaired mucosal sIgA transport"},{"approach":"Over-reliance on serum serology for disease monitoring","reason":"Patient's immunological profile makes serology structurally unreliable"},{"approach":"Prolonged gluten challenge for seroconversion","reason":"Only 2/22 seroconverted after 84g gluten × 6 weeks (Syage 2023; PMID 38140342); for compartmentalized disease yield even lower"},{"test":"IgG-based celiac serology as standalone test","reason":"If IgG1 deficiency impairs celiac-specific antibody production (core hypothesis), IgG-based tests are also unreliable — logical paradox"}]},"confidence_tiering":{"tier_1_established":[{"claim":"Anti-TG2 antibodies originate in gut mucosa","references":["Marzari 2001 PMID:11238668","Di Niro 2012 PMID:22366952","Iversen 2017 PMID:28877470"]},{"claim":"TG2-IgA deposits present in 96-100% of seronegative CD","references":["Salmi 2006 PMID:16571636","Koskinen 2010 PMID:19779364"]},{"claim":"Serum and secretory IgA independently regulated","references":["O'Mahony 1991 PMID:2032515"]},{"claim":"pIgR is sole mechanism for epithelial IgA transcytosis","references":["Shimada 1999 PMID:10553061","Johansen & Kaetzel 2011"]},{"claim":"OTA and MPA are documented immunotoxins","references":["Müller 1990","Keven 2003"]},{"claim":"TACI mutations cause selective IgG subclass and IgA deficiency","references":["Castigli 2005 PMID:16007086"]}],"tier_2_emerging":[{"claim":"Sequential IgG1→IgA class switching occurs in gut","references":["Siniscalco 2025 PMID:41253159"],"limitation":"Strong mouse data; human data from non-GALT sites"},{"claim":"Celiac villous atrophy reduces functional pIgR transport capacity","references":["Shiner & Ballard 1973 PMID:4586081"],"limitation":"Logical but never directly measured in celiac biopsies"},{"claim":"Mycotoxin exposure at observed levels impairs B-cell function","references":["Dortmans 2019","Böhm 2005"],"limitation":"Animal dose extrapolation; no human mucosal IgA studies"}],"tier_3_novel_hypothesis":[{"claim":"IgG1 deficiency impairs high-affinity mucosal IgA via disrupted sequential switching","basis":"Extrapolation from Siniscalco 2025 to this patient","status":"Mechanistically sound; entirely untested","key_gap":"No study has measured fecal sIgA in isolated IgG1 deficiency"},{"claim":"Double hit (production × transport) explains severity of fecal sIgA depletion","basis":"Mathematical/multiplicative reasoning","status":"Mechanistically coherent; no direct test possible"},{"claim":"Triple hit adding mycotoxins produces synergistic immunosuppression","basis":"Pharmacological reasoning (MPA inhibits proliferation-dependent CSR)","status":"Pharmacologically plausible; no combination data"},{"claim":"Anti-TG2 IgA trapped between failed luminal secretion and failed systemic spillover","basis":"Patient-specific integration of compartment model","status":"Explanatory model; consistent with data but unverifiable without tissue studies"}]},"supporting_metabolic_findings":{"arabinose":{"value":"elevated","interpretation":"Fungal/yeast overgrowth marker — consistent with mycotoxin-producing mold exposure"},"FIGLU":{"value":"elevated","interpretation":"Functional folate deficiency — impairs B-cell DNA synthesis and proliferation"},"suberic_acid":{"value":4.6,"unit":"mmol/mol creatinine","reference":"<1.9","interpretation":"Fatty acid beta-oxidation defect — mitochondrial dysfunction marker"},"vitamin_C":{"value":1.7,"unit":"mmol/mol creatinine","reference":"10-200","status":"LOW","interpretation":"Antioxidant depletion — may reflect oxidative stress from mycotoxins"}},"prognosis":{"systemic_IgG_IgG1":{"outlook":"Guarded — likely primary component","rationale":"Declined during strict GFD; suggests intrinsic defect","reversible_component":"OTA/MPA effects may allow partial improvement"},"mucosal_sIgA":{"outlook":"BETTER than systemic prognosis","rationale":"Measured during intermittent gluten period (2019-2025); may reflect recent reversible damage","reversibility":"Likely reversible with strict GFD + mucosal healing"},"key_prognostic_factors":["Speed and completeness of OTA/MPA elimination","Return to and maintenance of strict GFD","Achievement of complete mucosal healing","Presence/absence of TACI or other genetic defect","Vaccine response capability"]},"references":[{"id":"di_niro_2012","authors":"Di Niro R et al.","title":"High abundance of plasma cells secreting transglutaminase 2-specific IgA autoantibodies with limited somatic hypermutation in celiac disease intestinal lesions","journal":"Nat Med","year":2012,"volume":"18(3)","pages":"441-5","pmid":"22366952"},{"id":"iversen_2017","authors":"Iversen R et al.","title":"Strong Clonal Relatedness between Serum and Gut IgA despite Different Plasma Cell Origins","journal":"Cell Rep","year":2017,"volume":"20(10)","pages":"2357-2367","pmid":"28877470"},{"id":"lindeman_2024","authors":"Lindeman I et al.","title":"Chronic naive B cell recruitment underlies the extrafollicular anti-TG2 response in celiac disease","journal":"Cell Rep","year":2024,"volume":"43(4)","pages":"114045","pmid":"38578826"},{"id":"salmi_2006","authors":"Salmi TT et al.","title":"Immunoglobulin A autoantibodies against transglutaminase 2 in the small intestinal mucosa predict forthcoming coeliac disease","journal":"Gut","year":2006,"volume":"55(12)","pages":"1746-53","pmid":"16571636"},{"id":"korponay_szabo_2004","authors":"Korponay-Szabó IR et al.","title":"In vivo targeting of intestinal and extraintestinal transglutaminase 2 by coeliac autoantibodies","journal":"Gut","year":2004,"volume":"53(10)","pages":"1391-7","pmid":"15082580"},{"id":"koskinen_2010","authors":"Koskinen O et al.","title":"Gluten-dependent small bowel mucosal transglutaminase 2-specific IgA deposits in overt and mild enteropathy coeliac disease","journal":"J Clin Gastroenterol","year":2010,"volume":"44(7)","pages":"483-8","pmid":"19779364"},{"id":"siniscalco_2025","authors":"Siniscalco ER et al.","title":"Sequential class switching generates antigen-specific gut IgA from IgG1 B cells","journal":"Immunity","year":2025,"volume":"58(12)","pages":"3075-3093.e6","doi":"10.1016/j.immuni.2025.10.022","pmid":"41253159"},{"id":"shiner_1973","authors":"Shiner RJ, Ballard J","title":"Mucosal secretory IgA and secretory piece in adult coeliac disease","journal":"Gut","year":1973,"volume":"14(10)","pages":"778-83","pmid":"4586081","correction_note":"Earlier draft incorrectly cited as 1975"},{"id":"shimada_1999","authors":"Shimada S et al.","title":"Generation of polymeric immunoglobulin receptor-deficient mouse with marked reduction of secretory IgA","journal":"J Immunol","year":1999,"volume":"163(10)","pages":"5367-73","pmid":"10553061"},{"id":"omahony_1991","authors":"O'Mahony S et al.","title":"Dissociation between systemic and mucosal humoral immune responses in coeliac disease","journal":"Dig Dis Sci","year":1991,"volume":"36(6)","pages":"743-9","pmid":"2032515"},{"id":"kappler_2006","authors":"Kappler M et al.","title":"Detection of secretory IgA antibodies against gliadin and human tissue transglutaminase in stool to screen for coeliac disease in children","journal":"J Pediatr Gastroenterol Nutr","year":2006,"volume":"42(4)","pages":"429-32","pmid":"16377644","correction_note":"Earlier draft did not specify journal correctly"},{"id":"russell_2024","authors":"Russell AC et al.","title":"Gluten immunogenic peptides for monitoring gluten-free diet compliance","journal":"Nutrients","year":2024,"volume":"16(2)","pages":"234","pmid":"38257173"},{"id":"castigli_2005","authors":"Castigli E et al.","title":"TACI is mutant in common variable immunodeficiency and IgA deficiency","journal":"Nat Immunol","year":2005,"volume":"6(9)","pages":"895-901","pmid":"16007086"},{"id":"marzari_2001","authors":"Marzari R et al.","title":"Molecular dissection of the tissue transglutaminase autoantibody response in celiac disease","journal":"J Immunol","year":2001,"volume":"166(6)","pages":"4170-6","pmid":"11238668"},{"id":"xiong_2012","authors":"Xiong H et al.","title":"Sequential class switching is required for the generation of high affinity IgE antibodies","journal":"J Exp Med","year":2012,"volume":"209(2)","pages":"353-64","pmid":"22249450"},{"id":"volta_2016","authors":"Volta U et al.","title":"Seronegative celiac disease: Shedding light on an obscure clinical entity","journal":"Dig Liver Dis","year":2016,"pmid":"27352981"},{"id":"syage_2023","authors":"Syage JA et al.","title":"Gluten challenge and seroconversion in seronegative celiac disease","journal":"2023","pmid":"38140342"},{"id":"castelijn_2025","authors":"Castelijn DAR et al.","title":"HLA-DQ-gluten dextramer assay for celiac disease diagnosis","year":2025,"pmid":"40778297"}],"version_history":{"v1.0":"Initial analysis of fecal sIgA and mucosal immune function","v2.0":{"date":"2026-02-10","changes":["Shiner & Ballard date corrected (1975→1973)","SNCD prevalence corrected to 1.7-2.7% under strict criteria","Kappler journal attribution corrected","TACI/TNFRSF13B discussion and testing priority added","Salivary IgA added as critical discriminating test","IgG temporal trend integrated (decline during strict GFD 2013-2019)","Vaccine response testing added","TG2-IgA deposit sensitivity caveat added for combined SNCD + IgG subclass deficiency","Explicit three-tier evidence classification applied throughout","Internal contradiction resolved (impaired production vs assumed 100% sensitivity)","Siniscalco extrapolation hedging strengthened","IgG-based serology paradox noted in 'what to avoid'","IL-2 assay sensitivity limitation for HLA-DQ8+ explicitly stated"]}}}
